uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We are advancing a focused pipeline of innovative adeno-associated virus (AAV)-based gene therapies, and have entered late-stage clinical development in our lead program, hemophilia B. Our vision is to build an industry-leading global company that leverages its validated technology and manufacturing platform to deliver transformative gene therapies to patients with high unmet medical need.